An interventional study of SMART-IBD in Inflammatory Bowel Disease (IBD), IBD (Inflammatory Bowel Disease) and IBD - Inflammatory Bowel Disease, sponsored by Children's Hospital Medical Center, Cincinnati. Recruiting at 1 site in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-11-21.
Sponsored by Children's Hospital Medical Center, Cincinnati · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 463 studies in Inflammatory Bowel Diseases with a site in United States — 103 open to participants now, 124 under way, 6 of them phase 3. Inflammatory Bowel Diseases · United States.
Among the 463 studies in Inflammatory Bowel Diseases with a site in United States, this one is the 134th largest by planned enrollment of the 327 interventional ones that give a count, is one of 30 that started in 2025, is one of 131 with no phase, reaches primary completion later than 37 of the 121 other live ones, and was the 436th registered.
1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →103 of the 463 studies in Inflammatory Bowel Diseases with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18–80
Stanford University · Sites in United States
Ages 18+
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–85
Palisade Bio · Sites in United States, Canada, Czechia and 9 more countries
Ages 18–75
Eli Lilly and Company · Sites in United States, Canada, Denmark and 4 more countries
Ages 3 wk+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.
This study: 13 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
463 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 59 · Phase 2 83 · Phase 3 46 · Phase 4 31
First in 1995; this study’s year is marked. 30 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is close to the median of 68 across 875 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 50 across the 327 interventional studies, 134 across the 132 observational. Of the 301 that completed or were terminated, 120 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
132 of 463 have an industry lead sponsor. The 10 most frequent:
Children's Hospital Medical Center, Cincinnati is the lead sponsor of 673 studies on the registry; 129 are open to participants now.
Of its 57 completed or terminated interventional studies of FDA-regulated products, 32 (56%) have results posted.
Children's Hospital Medical Center, Cincinnati has 9 studies filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
43 of the studies in Inflammatory Bowel Diseases with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT06188793University of MichiganVirtual Reality (VR) -Directed Brain Gut Behavioral Treatment (BGBT) for Inflammatory Bowel Disease (IBD) Inpatients | 2026-12 |
| NCT04508088Massachusetts General HospitalSkeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease | 2026-12 |
| NCT07769437University Hospitals Cleveland Medical CenterNon-nutritive Sweeteners in Inflammatory Bowel Disease | 2026-12 |
Add all 43 to your calendar (.ics) → With an account.
Among the 463 studies in Inflammatory Bowel Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this trial is to test whether a smartphone app, SMART-IBD, is effective in improving medication adherence and self-management skills in adolescents with IBD. The investigators will conduct a randomized control trial to compare 35 youth (ages 13-17) with IBD using an app that contains daily symptom diaries, education content, medication reminders, as well as monthly engagement challenges to 35 youth in an attention control group that will complete daily diaries. The length of the intervention will include one month of baseline symptom and adherence collection, a baseline assessment, 5 months of intervention, and a post-treatment assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The SMART-IBD app consists of educational content, medication reminders, and monthly app engagement challenges. App users will participate in 5 monthly challenges that focus on topics such as adherence, sleep, and diary usage. Participants in this arm will complete one month of run-in diaries, a baseline assessment, 5 months of intervention, including daily symptom diaries, and a post-treatment assessment.
Behavioral: SMART-IBD
Participants in this arm will not receive any intervention content. Participants in this arm will complete one month of run-in diaries, a baseline assessment, 5 months of daily symptom diaries, and a post-treatment assessment.
Daily medication and diary completion reminders are provided to participants. Additional psychoeducational content regarding self-management skills will be provided in-app.
Medication adherence
Medication adherence will be measured by daily responses by participants to prompts in the SMART IBD app regarding whether each dose was taken for each medication. A mean adherence score will be calculated across medications for each participant for the 28 day periods at baseline and post-treatment.
Time frame: 6 months
Disease Activity
PROs will be collected regarding composite disease activity comprised of fecal calprotectin, stool frequency, and rectal bleeding for ulcerative colitis and fecal calprotectin, stool frequency, and abdominal pain for Crohn's. Stool samples collected at baseline and post-assessment will also be utilized to assess diseases activity.
Time frame: 6 months
Sleep Duration
Sleep duration will be assessed via the SMART IBD App diary on a scale of 0-18 hours or more with half hour increments. Participants in both arms will report sleep duration via the diary.
Time frame: 6 months
Stress
Stress will be assessed via the SMART IBD App diary on a scale of 0-10, where 0 is no stress and 10 is highest stress. Participants in both arms will report stress via the diary.
Time frame: 6 months
Started Oct 2025 (actual). Primary completion is estimated for Feb 2027, 16 months after the start.
Of 285 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 16 months is below that.
Counting every sponsor, half of 299 studies reached it within 26 months; a quarter within 14 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Children's Hospital Medical Center, Cincinnati →